Human Papillomavirus (HPV) Associated Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2021, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape.Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Human papillomavirus (HPV) has been found to be associated with several types of cancer. Risk factors include smoking, weakened immune system, long-term oral contraceptive use and chronic inflammation. Human papillomavirus (HPV) associated cancer have no symptoms until it is quite advanced, very serious and hard to treat.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Papillomavirus (HPV) Associated Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 29, 17, 40, 7 and 2 respectively.

Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 2 molecules, respectively.Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer (Oncology).- The pipeline guide reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. – The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.- The pipeline guide reviews key companies involved in Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics and enlists all their major and minor projects.- The pipeline guide evaluates Human Papillomavirus (HPV) Associated Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. – The pipeline guide reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.- Find and recognize significant and varied types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology).- Classify potential new clients or partners in the target demographic.- Develop tactical initiatives by understanding the focus areas of leading companies.- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.- Formulate corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline depth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Abion Inc

Abivax SA

Advaxis Inc

Anteris Technologies Ltd

Antiva Biosciences Inc

Apimeds Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Auro Vaccines LLC

Avalia Immunotherapies Ltd

Avidea Technologies Inc

Beijing Recreation Guards Biotechnology Co Ltd

Beijing Shenzhou Cell Biotechnology Group Co Ltd

BioMed Valley Discoveries Inc

Biond Biologics Ltd

BioNTech SE

Blue Sky Immunotherapies GmbH

Bristol Myers Squibb Co

Cellid Co Ltd

Chain Biotechnology Ltd

Chengdu Institute of Biological Products Co Ltd

Cue Biopharma Inc

Cullinan Oncology LLC

Elicio Therapeutics Inc

eTheRNA Immunotherapies NV

Etubics Corp

EyeGene Inc

Genexine Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

Hookipa Pharma Inc

iBio Inc

Immunomic Therapeutics Inc

IMV Inc

Innovene

Inovio Pharmaceuticals Inc

Inthera Bioscience AG

Iovance Biotherapeutics Inc

ISA Pharmaceuticals BV

Ispin Inc

Merck & Co Inc

Merck KGaA

Myrio Therapeutics Pty Ltd

OncoNano Medicine Inc

Onconova Therapeutics Inc

Oxford Vacmedix UK Ltd

Papivax LLC

Pathovax LLC

Pattern Pharma Inc

PDS Biotechnology Corp

Precigen Inc

Privo Technologies Inc

Rafjik Inc

Repertoire Immune Medicines Inc

Rottapharm Biotech Srl

Rubius Therapeutics Inc

Shanghai Bovax Biotechnology Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shantha Biotechnics Pvt Ltd

Shuttle Pharmaceuticals Inc

Sirnaomics Inc

Symvivo Inc

TCR Cure Biopharma Technology Co Ltd

Tessa Therapeutics Ltd

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Touchlight Genetics Ltd

Transgene SA

Turnstone Biologics Inc

UbiVac LLC

Vaccibody AS

Vaccitech plc

Vault Pharma Inc

Vectorite Biomedical Inc

ViciniVax BV

Vir Biotechnology Inc

Virion Therapeutics LLC

Virometix AG

VLP The Vaccines Company SL

Voltron Therapeutics Inc

West Lake Biomedical Technology (Hangzhou) Co Ltd

Xiamen Innovax Biotech Co Ltd

Table of Contents

Table of Contents

Introduction

Human Papillomavirus (HPV) Associated Cancer - Overview

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment

Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development

Human Papillomavirus (HPV) Associated Cancer - Drug Profiles

Human Papillomavirus (HPV) Associated Cancer - Dormant Projects

Human Papillomavirus (HPV) Associated Cancer - Discontinued Products

Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Abion Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Abivax SA, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Advaxis Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Anteris Technologies Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Antiva Biosciences Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Apimeds Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Astex Pharmaceuticals Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by AstraZeneca Plc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Atara Biotherapeutics Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Auro Vaccines LLC, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Avalia Immunotherapies Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Avidea Technologies Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Beijing Recreation Guards Biotechnology Co Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by BioMed Valley Discoveries Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Biond Biologics Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by BioNTech SE, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Blue Sky Immunotherapies GmbH, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Bristol Myers Squibb Co, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cellid Co Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Chain Biotechnology Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Chengdu Institute of Biological Products Co Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cue Biopharma Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cullinan Oncology LLC, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Elicio Therapeutics Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by eTheRNA Immunotherapies NV, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Etubics Corp, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by EyeGene Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Genexine Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Gilead Sciences Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by GlaxoSmithKline Plc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Hookipa Pharma Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by iBio Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Immunomic Therapeutics Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by IMV Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Innovene, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inovio Pharmaceuticals Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inthera Bioscience AG, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Iovance Biotherapeutics Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by ISA Pharmaceuticals BV, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Ispin Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Merck & Co Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Merck KGaA, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Myrio Therapeutics Pty Ltd, 2021

Human Papillomavirus (HPV) Associated Cancer – Pipeline by OncoNano Medicine Inc, 2021

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, 2021

Human Papillomavirus (HPV) Associated Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports